{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:17:00Z","timestamp":1788441420320,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"DOI":"10.7759\/cureus.115715","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:39:42Z","timestamp":1788439182000},"source":"Crossref","is-referenced-by-count":0,"title":["A Review of Thrombopoietin Receptor Agonists and Subsequent Development of Thrombosis: Exploring a Hematologic Paradox"],"prefix":"10.7759","author":[{"given":"Gillian","family":"Graifman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranya","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Varma","family":"C P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2247-4209","article-title":"Update on the use of thrombopoietin-receptor agonists in pediatrics","volume":"44","author":"Gebetsberger J","year":"2024","unstructured":"Gebetsberger J, Streif W, Dame C. Update on the use of thrombopoietin-receptor agonists in pediatrics. Hamostaseologie. 2024, 44:316-25. 10.1055\/a-2247-4209","journal-title":"Hamostaseologie"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima W","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019, 104:1112-23. 10.3324\/haematol.2018.212845","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.32143","article-title":"Real-world use of avatrombopag in children and adolescents with immune thrombocytopenia","volume":"73","author":"Harris EM","year":"2026","unstructured":"Harris EM, Montcrieff C, O'Farrell C, et al.. Real-world use of avatrombopag in children and adolescents with immune thrombocytopenia. Pediatr Blood Cancer. 2026, 73:e32143. 10.1002\/pbc.32143","journal-title":"Pediatr Blood Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391107","article-title":"Thrombopoietin","volume":"339","author":"Kaushansky K","year":"1998","unstructured":"Kaushansky K. Thrombopoietin. N Engl J Med. 1998, 339:746-54. 10.1056\/NEJM199809103391107","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter DJ","year":"2013","unstructured":"Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013, 98:10-23. 10.1007\/s12185-013-1382-0","journal-title":"Int J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yapd.2024.02.007","article-title":"Pediatric immune thrombocytopenia","volume":"71","author":"Gotesman M","year":"2024","unstructured":"Gotesman M, Shear M, Raheel S, Procassini M, Panosyan EH. Pediatric immune thrombocytopenia. Adv Pediatr. 2024, 71:229-40. 10.1016\/j.yapd.2024.02.007","journal-title":"Adv Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042163","article-title":"Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options","volume":"25","author":"Mititelu A","year":"2024","unstructured":"Mititelu A, Onis\u00e2i MC, Ro\u0219ca A, Vl\u0103d\u0103reanu AM. Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options. Int J Mol Sci. 2024, 25:10.3390\/ijms25042163","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert C","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019, 3:3829-66. 10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"ref9","article-title":"Thrombopoietin receptor agonists","author":"Ijaz A","year":"2026","unstructured":"Ijaz A, Patel P. Thrombopoietin receptor agonists. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.07.016","article-title":"Impact of thrombopoietin receptor agonists on platelet transfusion requirements in myelodysplastic syndromes: an updated systematic review and meta-analysis","volume":"25","author":"Aziz N","year":"2025","unstructured":"Aziz N, Nabi W, Umer HM, et al.. Impact of thrombopoietin receptor agonists on platelet transfusion requirements in myelodysplastic syndromes: an updated systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2025, 25:e1065-76. 10.1016\/j.clml.2025.07.016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley DM","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, et al.. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017, 376:1540-50. 10.1056\/NEJMoa1613878","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019051","article-title":"American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia","volume":"10","author":"Scheinberg P","year":"2026","unstructured":"Scheinberg P, O'Neal DA, Basquiera AL, et al.. American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia. Blood Adv. 2026, 10:5962-90. 10.1182\/bloodadvances.2025019051","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2026.04.002","article-title":"Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort","volume":"24","author":"Zordan J","year":"2026","unstructured":"Zordan J, Zadro Y, Sommet A, Lapeyre-Mestre M, Moulis G, Lafaurie M. Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort. J Thromb Haemost. 2026, 24:2567-78. 10.1016\/j.jtha.2026.04.002","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta\u2011analysis of randomized controlled trials","volume":"20","author":"Shen N","year":"2024","unstructured":"Shen N, Qiao J, Jiang Y, et al.. Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta\u2011analysis of randomized controlled trials. Biomed Rep. 2024, 20:44. 10.3892\/br.2024.1732","journal-title":"Biomed Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-339-8_2","article-title":"Platelet physiology","volume":"992","author":"Linden MD","year":"2013","unstructured":"Linden MD. Platelet physiology. Methods Mol Biol. 2013, 992:13-30. 10.1007\/978-1-62703-339-8_2","journal-title":"Methods Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07323.x","article-title":"Virchow and his triad: a question of attribution","volume":"143","author":"Bagot CN","year":"2008","unstructured":"Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008, 143:180-90. 10.1111\/j.1365-2141.2008.07323.x","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour R","year":"2022","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al.. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022, 386:11-23. 10.1056\/NEJMoa2109965","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel JB","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN, et al.. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007, 357:2237-47. 10.1056\/NEJMoa073275","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath J","year":"2021","unstructured":"Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021, 81:1285-305. 10.1007\/s40265-021-01553-7","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006014","article-title":"A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia","volume":"7","author":"Grainger J","year":"2023","unstructured":"Grainger J, Bussel J, Tarantino M, et al.. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia. Blood Adv. 2023, 7:396-405. 10.1182\/bloodadvances.2021006014","journal-title":"Blood Adv"},{"key":"ref21","unstructured":"Nplate\u00ae (romiplostim). (2026). Accessed. August 2, 2026: https:\/\/www.nplatehcp.com\/?gclsrc=aw.ds&gad_source=1&gad_campaignid=23263297114&gclid=EAIaIQobChMI89Woy7GolgMVKmQPAh1...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"Terrault N","year":"2018","unstructured":"Terrault N, Chen YC, Izumi N, et al.. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018, 155:705-18. 10.1053\/j.gastro.2018.05.025","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14395","article-title":"Avatrombopag for the treatment of immune thrombocytopenia","volume":"114","author":"Labanca C","year":"2025","unstructured":"Labanca C, Vigna E, Martino EA, et al.. Avatrombopag for the treatment of immune thrombocytopenia. Eur J Haematol. 2025, 114:733-46. 10.1111\/ejh.14395","journal-title":"Eur J Haematol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01197-8","article-title":"Lusutrombopag: a review in thrombocytopenia in patients with chronic liver disease prior to a scheduled procedure","volume":"79","author":"Shirley M","year":"2019","unstructured":"Shirley M, McCafferty EH, Blair HA. Lusutrombopag: a review in thrombocytopenia in patients with chronic liver disease prior to a scheduled procedure. Drugs. 2019, 79:1689-95. 10.1007\/s40265-019-01197-8","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393900","article-title":"In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation","volume":"119","author":"Psaila B","year":"2012","unstructured":"Psaila B, Bussel JB, Linden MD, et al.. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012, 119:4066-72. 10.1182\/blood-2011-11-393900","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102342","article-title":"Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes","volume":"8","author":"Goncalves I","year":"2024","unstructured":"Goncalves I, Lewis C, Grainger B, et al.. Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes. Res Pract Thromb Haemost. 2024, 8:102342. 10.1016\/j.rpth.2024.102342","journal-title":"Res Pract Thromb Haemost"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00509-z","article-title":"Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis","volume":"21","author":"Dong Y","year":"2023","unstructured":"Dong Y, Xia Z, Zhou J, Hu Y, Yue M, Wang Y, Hu M. Risk of thrombotic events in immune thrombocytopenia patients treated with thrombopoietic agents: a systematic review and meta-analysis. Thromb J. 2023, 21:69. 10.1186\/s12959-023-00509-z","journal-title":"Thromb J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle S","year":"2013","unstructured":"Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013, 121:4782-90. 10.1182\/blood-2012-12-467068","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.11.001","article-title":"Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis","volume":"15","author":"Moulis G","year":"2016","unstructured":"Moulis G, Audemard-Verger A, Arnaud L, et al.. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis. Autoimmun Rev. 2016, 15:203-9. 10.1016\/j.autrev.2015.11.001","journal-title":"Autoimmun Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter DJ","year":"2013","unstructured":"Kuter DJ, Bussel JB, Newland A, et al.. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013, 161:411-23. 10.1111\/bjh.12260","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong RS","year":"2017","unstructured":"Wong RS, Saleh MN, Khelif A, et al.. Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017, 130:2527-36. 10.1182\/blood-2017-04-748707","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak W","year":"2018","unstructured":"Jurczak W, Chojnowski K, Mayer J, et al.. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018, 183:479-90. 10.1111\/bjh.15573","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)","volume":"70","author":"Peck-Radosavljevic M","year":"2019","unstructured":"Peck-Radosavljevic M, Simon K, Iacobellis A, et al.. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019, 70:1336-48. 10.1002\/hep.30561","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema M","year":"2022","unstructured":"Tjepkema M, Amini S, Schipperus M. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022, 171:103581. 10.1016\/j.critrevonc.2022.103581","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70075","article-title":"Thromboembolic risk of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis integrating randomized controlled trials and prospective evidence","volume":"45","author":"Dai MF","year":"2025","unstructured":"Dai MF, Chong GW, Xin WX, et al.. Thromboembolic risk of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis integrating randomized controlled trials and prospective evidence. Pharmacotherapy. 2025, 45:764-73. 10.1002\/phar.70075","journal-title":"Pharmacotherapy"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03830.x","article-title":"Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)","volume":"8","author":"Gernsheimer TB","year":"2010","unstructured":"Gernsheimer TB, George JN, Aledort LM, et al.. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010, 8:1372-82. 10.1111\/j.1538-7836.2010.03830.x","journal-title":"J Thromb Haemost"},{"key":"ref37","unstructured":"PROMACTA\u00ae (eltrombopag). (2025). Accessed. August 2, 2026: https:\/\/us.promacta.com\/."},{"key":"ref38","unstructured":"DOPTELET\u00ae (avatrombopag). (2025). Accessed. August 2, 2026: https:\/\/www.doptelethcp.com\/?utm_source=Google&utm_medium=Paid-Search&utm_campaign=SOBI-Doptelet-Growing-ITP-SOBI-Dop...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/529074-a-review-of-thrombopoietin-receptor-agonists-and-subsequent-development-of-thrombosis-exploring-a-hematologic-paradox","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:39:43Z","timestamp":1788439183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/529074-a-review-of-thrombopoietin-receptor-agonists-and-subsequent-development-of-thrombosis-exploring-a-hematologic-paradox"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.115715","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}